Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Net Cash Flow (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Net Cash Flow for 6 consecutive years, with -$3.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 94.1% year-over-year to -$3.8 million, compared with a TTM value of -$8.0 million through Dec 2025, up 89.1%, and an annual FY2025 reading of -$8.0 million, up 89.1% over the prior year.
  • Net Cash Flow was -$3.8 million for Q4 2025 at Cytek Biosciences, down from $17.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $216.9 million in Q3 2021 and bottomed at -$166.0 million in Q1 2023.
  • Average Net Cash Flow over 5 years is -$3.9 million, with a median of -$3.0 million recorded in 2025.
  • The sharpest move saw Net Cash Flow surged 43113.35% in 2021, then tumbled 8656.12% in 2023.
  • Year by year, Net Cash Flow stood at -$12.8 million in 2021, then plummeted by 219.7% to -$41.0 million in 2022, then soared by 111.76% to $4.8 million in 2023, then plummeted by 1449.0% to -$65.1 million in 2024, then soared by 94.1% to -$3.8 million in 2025.
  • Business Quant data shows Net Cash Flow for CTKB at -$3.8 million in Q4 2025, $17.0 million in Q3 2025, and -$18.9 million in Q2 2025.